Patient-reported outcomes in real-world use of benralizumab in patients with severe eosinophilic asthma in Belgium

Trial Identifier: D3250R00059
Sponsor: AstraZeneca
NCTID:: NCT04221802
Start Date: December 2019
Primary Completion Date: May 2024
Study Completion Date: May 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Belgium, N/A Aalst, N/A, Belgium, 9300
Belgium, N/A Brussels, N/A, Belgium, 1070
Belgium, N/A Bruxelles, N/A, Belgium, 1200
Belgium, N/A Bruxelles, N/A, Belgium, 1160
Belgium, N/A Charleroi, N/A, Belgium, 6042
Belgium, N/A Edegem, N/A, Belgium, 2650
Belgium, N/A Erpent, N/A, Belgium, 5101
Belgium, N/A Genk, N/A, Belgium, 3600
Belgium, N/A Gosselies, N/A, Belgium, 6041
Belgium, N/A Kortrijk, N/A, Belgium, 8500
Belgium, N/A La Louviere, N/A, Belgium, 7100
Belgium, N/A Leuven, N/A, Belgium, 3000
Belgium, N/A Liege, N/A, Belgium, 4000
Belgium, N/A Mechelen, N/A, Belgium, 2800
Belgium, N/A Merksem (Antwerpen), N/A, Belgium, 2170
Belgium, N/A Roeselare, N/A, Belgium, 8800